With progression of the disease, bone metastases
alter the integrity of the skeletal system leading to pathological bone fractures and bone pain, which affects the quality of life of the patient.
During the same period, we worked with clinical collaborators at Duke Cancer Institute to plan our next trial for GMI-1359, a dual antagonist of E-selectin and CXCR-4, and defined individuals with breast cancer and bone metastases
as our initial target study population," said CEO Rachel King.
The incidence of bone metastases
varies significantly depending on the primary site, with breast and prostate cancer accounting for up to 70% of patients with metastatic disease .
More than 70% of patients with solid tumors develop painful bone metastases
during the course of their disease in the spine, pelvis, and extremities1.
in HCC are uncommon with an incidence of 3% to 20%.1 Screening for bone metastasis is not a routine practice.
Sr89 works by delivering radiation local to the bone metastases
that results in pain relief by selectively targeting and accumulating in metastatic bone lesions with minimal risk of toxicity to surrounding normal tissue, concluded the company.
After lung and liver, osseous metastases, particularly osteolytic bone metastases
, are among the most common types of metastases to occur in advanced cancer, and the majority of the affected patients suffer from severe pain refractory to common treatment methods (2, 37).
14, 2018 (HealthDay News) -- A model with four categories has been developed to stratify patients with symptomatic long bone metastases
(LBM) based on their expected survival, according to an article published online Feb.
Lytic bone metastases
are due to a variety of primary tumors and are more common than sclerotic metastases .
Amgen's sBLA for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases
from solid tumors, has been approved to include multiple myeloma.
of breast cancer are frequently found in the rib, sternum, vertebrae, or pelvis and are refractory to radiation therapy combined with standardized HER2-binding monoclonal antibody and/or endocrine treatments and, if necessary, cytotoxic chemotherapy comprising a widespread regimen such as cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) .